



#12
6/6/95
D-45113

TFM

RECEIVED

MAY 22 1995

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : WYBE MARTIN KAST ET AL
Serial No. : 08/170,344 Examiner N. Minnifield
Filed : March 10, 1994 Art Unit 1813
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN
HUMAN T CELL RESPONSE INDUCING COMPOSITIONS

May 11, 1995

Assistant Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

SUPPLEMENTAL COMMUNICATION

This Communication is supplemental to applicants' Amendment filed April 7, 1994 in the above-identified application in response to the then-outstanding Office Action of October 4, 1995.

In this response filed by applicants it is called to the Examiners attention that on page 6, top or first line, mention is made of:

"a 3 mer peptide."

This is a typographical error and should correctly read:

--an 8-mer --.

Further, it is pointed out that an additional typographical error appears on page 11, third line from the bottom, which reads:

"seven are not applicable to applicants' claimed invention one"

This line should correctly read:

--seven are not applicable to applicants' claimed invention.
One--

The typographical error is the omission of the period sign (.) after "invention". Applicants' attorney regrets the typographical errors appearing in applicants' Amendment.

Applicants wish to take this opportunity to additionally add to applicants' arguments and points of distinction as to how applicants' claimed invention distinguishes over the disclosures of Schoolnik et al.

Referring now to applicants' response at page 10, last paragraph, the bottom or last five lines thereof should more accurately correctly read:

--Therefore, this peptide will not bind to this HLA molecule. Schoolnik's peptide No. 5 does contain an anchor residue for HLA-A 0301 at the C-terminal end, namely, an R. However, there is no anchor for that HLA molecule present on position 2. Therefore, this peptide will not bind to HLA-A 0301.--

At that portion of applicants' argument, applicants' attorney

had misread applicants' instructions and argument with respect to the disclosures and teachings of Schoolnik et al, as now corrected hereinabove. The Examiner can now more readily and correctly see how the Schoolnik et al peptide and disclosure differs from applicants' disclosure and teachings.

It is respectfully requested that the Examiner carefully consider applicants' arguments in the light of this indicated correction for a better understanding and appreciation of how applicants' invention patentably distinguishes over the references cited and the prior art.

Respectfully submitted,

*I hereby certify that this
paper is being deposited this
date with the U.S. Postal
Service in first class mail
addressed to Commissioner of
Patents and Trademarks
Washington, D.C. 20231*

Thomas F. Moran May 14, 1995
Thomas F. Moran - Date
Reg. No. 16579

Thomas F. Moran
Thomas F. Moran - Reg. No. 16579
Attorney for Applicant(s)
COOPER & DUNHAM LLP
1185 AVENUE OF AMERICAS
NEW YORK, NY 10036
TEL: 212-278-0400